Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
March 17 2017 - 4:07PM
Edgar (US Regulatory)
17 March 2017
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen,
Re: Notice of disclosure filed in Securities Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of
2012 and Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and
Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that GlaxoSmithKline plc has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2016,
which was filed with the Securities and Exchange Commission on 17, March 2017. The disclosure can be found on page two of the Annual Report on Form 20-F, which incorporates by reference the information set forth under the heading “Section
13(r) of the US Securities Exchange Act” on page 271 of Exhibit 15.2 to the Annual Report on Form 20-F, and is incorporated by reference herein.
Respectfully submitted,
|
|
|
|
|
GlaxoSmithKline plc
|
|
|
|
|
By:
|
|
/s/ Simon Dingemans
|
|
Name:
|
|
Simon Dingemans
|
|
Title:
|
|
Chief Financial Officer
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
